LY3962673

Other Medications

EU Experimental ES Not available 1 Clinical Trials

Description

LY3962673 is under investigation for the treatment of metastatic colorectal cancer (mCRC) in patients who have progressed on standard therapies. Its efficacy and safety are currently being evaluated in clinical trials, with preliminary data suggesting potential activity in this patient population.

Mechanism of Action

LY3962673 is an investigational agent that targets the Wnt/ -catenin signaling pathway, which plays a critical role in colorectal cancer cell proliferation and survival.

Side Effects

Fatigue; Nausea; Diarrhea; Elevated liver enzymes

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT06586515 Phase 1
Recruiting
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
United States, Canada, China, France, Germany, Ireland, Italy, Japan, Spain

Quick Info

CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
786 trials
Leucovorin
Other Medications
647 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.